Indian drugmakers Eris Lifesciences, Wockhardt and Lupin are prepping to cash in when Danish company Novo Nordisk bows out of the human insulin pen market by the end of this year and creates an opportunity estimated to be worth Rs 600-800 crore in the domestic market.
Some self-use disposable pens are pre-filled with insulin and others can be reused with new cartridges.
Uploaded by:
Rediff Video Desk
on Thu, 25 Sep 2025 13:42:28 +0530
Views: 13
Tags: Drugmakers look to fill Rs 600 cr Novo vacuum